After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

After its disappointing Rova-T flop last month, AbbVie is shoring up its solid tumor bets with a freshly inked research deal that should elicit new strategies for tumor attack.